Introduction: Elastic compression stockings (ECSs) are used to treat symptoms of ve-
Essentials
• Noncompliance with elastic compression stockings may limit their therapeutic efficacy in people with chronic venous insufficiency.
• We aimed to identify reasons for and predictors of stocking noncompliance in the SOX Trial population.
• Aversive aspects of compression stockings and patient behaviors were shown to be important reasons for noncompliance.
• Improving the appeal and tolerability of compression stockings and education directed at modifying patient behaviors may improve compliance.
| INTRODUCTION
Elastic compression stockings (ECSs) reduce venous hypertension and venous stasis in the lower extremities, and are frequently used to prevent and treat venous insufficiency, a prevalent and costly chronic condition.
1,2 However, many patients prescribed ECSs do not fill their prescription 3 or fill their prescription but do not wear their ECSs. 4 Thus, lack of compliance might be an important limitation to achieving optimal effectiveness of ECSs.
Overall, compliance with ECSs has been inadequately reported in the literature, with nearly half of studies either not reporting compliance or poorly describing it. 4 However, in one study, noncompliance to ECSs was reported in two-thirds of patients, 5 and a recent systematic review of multiple studies of ECSs reported that one-third of patients were noncompliant. 4 Understanding reasons for patients' noncompliance with ECSs could lead to improvement in the design and use of compression stockings for optimal patient benefit.
The SOX Trial assessed the effectiveness of ECSs to prevent the postthrombotic syndrome (PTS) after deep vein thrombosis (DVT).
6
During the trial, detailed information on use of study stockings and reasons for nonuse was collected but has not yet been reported in full. In the current analysis, we aimed to describe patient-reported reasons for nonuse of ECSs in the SOX Trial population and to identify predictors of noncompliance.
| METHODS
The SOX Trial was a multicenter randomized placebo controlled trial (n = 803) of active ECSs vs. placebo ECSs worn for 2 years after a first, symptomatic, proximal DVT to prevent the development of PTS. 6 Exclusion criteria for the SOX Trial included contraindication to the use of ECSs (eg, allergy or severe arterial claudication), an expected life span of <6 months, geographic inaccessibility precluding return for follow-up visits, inability to apply stockings, or received thrombolytic therapy for the initial treatment of acute DVT.
6
Active ECSs were knee-length 30 to -40 mm Hg (class II) graduated ECSs; placebo ECSs were manufactured to look identical to active ECSs but lacked therapeutic compression. Both active ECSs and placebo ECSs were provided free of charge to study participants and replaced every 6 months. Sizing was based on leg measurements performed by trained study nurses at each study visit.
Patients were asked to wear the study stockings on the DVTaffected leg daily for up to 24 months, and attended follow-up visits at 1, 6, 12, 18, and 24 months. At each follow-up visit, patients were asked how many days per week they wore the study stockings (response options: every day; 3-6 days per week; 1-2 days per week; less than once per week) and, if not worn daily, were prompted to specify the reason(s) (response options: difficult to put on; difficult to remove; not helpful; make symptoms worse; or alternative reason specified by patient). Reasons were grouped into 4 broad categories, as described below.
Reasons for nondaily use of ECSs were tabulated. As in the main SOX Trial paper, 6 overall compliance with ECSs over follow-up ("ECS compliers") was defined as ECSs worn for ≥3 days per week.
| Statistical analysis
We summarized demographic and clinical characteristics of study subjects as means and standard deviations or proportions, as appropriate. Reasons for not wearing stockings daily were compared in the active ECS and placebo ECS groups using the chi-square or
Fisher exact test, as appropriate. We used multiple logistic regression modeling to examine the association between being an ECS noncomplier and age, sex, body mass index (BMI), cigarette smoking, level of education, Villalta score at baseline (an indicator of severity of acute DVT symptoms/signs), study intervention group (ie, active vs. placebo ECSs), and category of reason at the 1-month visit for not wearing study stockings daily. In the regression model, all endorsed or specified reasons for not wearing study stockings daily were categorized as "behavior-related," "aversive aspects of stockings," "other reasons," or "no reason provided" (reference category). "Other reasons" were those outside the patient's control, for example, delayed delivery of study stockings or temporary prescription of nonstudy stockings by the patient's treating physician. As a sensitivity analysis, we repeated the multiple logistic regression after removing patients who had "other reasons" for not wearing study stockings daily. We performed all statistical analyses using SAS Software (version 9.4, SAS Institute Inc, Cary, NC, USA).
| RESULTS
Among the 776 study patients who had at least 1 follow-up visit, 61%
were male, mean age was 55.1 years, and mean BMI was 29.0 kg/m 2 .
The most proximal extent of DVT was femoral or popliteal vein in 62% of patients and iliac or common femoral vein in 38% of patients.
Additional baseline characteristics are shown in Table 1 .
As was reported in the main paper, use of study stockings at each visit was similar in the active ECS and placebo ECS groups. reason endorsed at all study visits among the options "difficult to put
on," "difficult to remove," "not helpful," or "make symptoms worse"
was "difficult to put on," which was endorsed more frequently by patients randomized to active ECSs than placebo ECSs. Among patients who selected "alternative reason" for nondaily use of study stockings, the reasons specified fell into 3 main thematic categories (Table 3 ; Figure 1 ): (1) (Figure 2 ).
Female sex, cigarette smoking, and lower BMI also tended to predict being an ECS noncomplier (ORs, 0.05 < P < 0.1) (Figure 2 
| DISCUSSION
During the SOX Trial, investigators obtained information from study participants regarding their use of assigned ECSs at each study visit.
In this article, we report detailed analyses on the use of study stockings and reasons for and predictors of noncompliance. Although overall compliance during the study was similar between the 2 groups at 2 years, more patients assigned to placebo ECSs reported using their ECSs daily at the 1-month visit than those assigned to active ECSs. This may relate to greater ease in applying and removing a stocking without therapeutic compression. This difference was no longer apparent after 1 month, perhaps because those assigned to active ECSs became more used to applying their stockings.
Daily use of ECSs decreased over the 2-year study period in both the active and placebo ECS groups, to just over 50% at More active ECS patients than placebo ECS patients in our study identified "difficult to put on" as the reason for less than daily usage at multiple follow-up visits (eg, 1 month, 36.6% vs. 11.6%; 6 months, We found that being female, a smoker, and having lower BMI were modest independent predictors of ECS noncompliance during study follow-up. It is possible that women were less compliant than men because of the aesthetic concerns that ECSs may present. However, in contrast to our study, women have not previously been shown to be less compliant with ECSs, with the largest study (3144 patients) reporting similar compliance in men and women (39% and 38%, respectively). 5 In a smaller study of 84 patients assigned ECSs after DVT for the prevention of PTS, men were found to be 4 times less compliant than women, albeit with a wide CI (OR, 4.1 [CI, 1.0-16.0]). 7 The authors did not speculate as to the reasons for sex differences in ECS compliance. Cigarette smoking has been found to be a predictor of noncompliance with prescribed therapy across several fields of research, [8] [9] [10] [11] [12] [13] [14] [15] [16] and smoking cessation has been reported to be predictive of increased adherence to therapy. 17 To our knowledge, cigarette smoking has not previously been reported as a predictor of noncompliance with compression stocking use. Higher BMI has been associated with less willingness to adhere to general health care requests/recommendations and to wear custom-made footwear to prevent diabetic ulcers than patients with lower BMIs, 18, 19 and among patients with chronic venous insufficiency, BMI was significantly associated with less compliance with compression therapy. 20 Conversely, as patients with higher BMI are more likely to have preexisting or to develop higher-grade chronic venous insufficiency, 21 it is possible that higher-BMI patients in our shown. # Being an "ECS complier" during the SOX Trial was defined a priori as patients who reported any stocking use on 3 or more out of 5 visits (ie, 1, 6, 12, 18, 24 months) and at these visits reported using stockings ≥3 days per week, for patients who attended all 5 study follow-up visits, and patients who reported any stocking use on ≥2 visits and at these visits reported using stockings ≥3 days per week, for patients who attended <5 follow-up visits. All other patients, as well as patients with 0 or 1 attended follow-up visit, were considered ECS noncompliers. *Reference category: No school or primary school only. **We categorized the reasons provided for not wearing stockings daily at the 1-month follow-up visit (ie, information from Tables 2 and 3 ) into 1 of 4 categories: aversive aspects of ECS (n = 128), behavior related (n = 36), other reason (n = 6), or no reason provided (n = 594) (reference category). BMI, body mass index; ECSs, elastic compression stockings Our study has several strengths. As this was a secondary analysis of a multicenter randomized trial, the inception population was well defined, and baseline characteristics were well documented.
Detailed information on stocking compliance and reasons for noncompliance were prospectively collected at each study follow-up visit.
Our study also has certain limitations. Compliance was assessed by patient self-report, and we cannot be certain that this reflects the actual use of stockings by patients. The patients in this cohort were given study stockings free of charge, which were rates of use of ECSs have been reported to be similar whether prescribed for prevention of PTS or treatment of venous insufficiency. 4 Therefore, our results may be generalizable to patients using ECSs for treatment of acute DVT symptoms or chronic venous insufficiency, including PTS. Finally, we acknowledge that in the SOX Trial, wearing a graduated ECS for 2 years after DVT did not reduce the incidence of PTS, which could call into question the relevance of our compliance analysis. However, as compression stockings are commonly used to treat PTS and other forms of chronic venous insufficiency, understanding factors that influence compliance remains relevant.
In conclusion, the most frequent predictors of being an ECS noncomplier were aversive aspects of ECSs and patient behavior-related factors. As ECSs are used in clinical practice to manage symptoms of acute and chronic venous disease, including PTS, our results provide insight into why patients do not wear ECSs, and suggest that improving the appeal and tolerability of ECSs, as well as education directed at modifying patient behaviors, may improve stocking compliance. 
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